Latest News and Press Releases

In data presented at SABCS23, DCISionRT changed radiation therapy decisions in 41% of DCIS patients

PreludeDx today announced that data will be presented in two separate poster presentations at the 2023 San Antonio Breast Cancer Symposium (SABCS).

LAGUNA HILLS, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Prelude Corporation (PreludeDx), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced study...

LAGUNA HILLS, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced it...

SEATTLE, WA--(Marketwired - Apr 2, 2014) - Atossa Genetics, Inc. (NASDAQ: ATOS) announced today that Ben R. Chen has joined the Company as Senior Vice President of Global Regulatory Affairs and...

SEATTLE, WA--(Marketwired - Sep 24, 2013) - Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, announced today that Kyle Guse, Chief Financial Officer & General Counsel,...

SEATTLE, WA--(Marketwired - Sep 19, 2013) - Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, will display its ForeCYTE Breast Health Test at the Pri-Med East 2013 Conference...

LOS ANGELES, CA--(Marketwired - Sep 16, 2013) - Seattle-based Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, today announced its sponsorship of the Los Angeles premiere of...

SEATTLE, WA--(Marketwired - Sep 12, 2013) - The ForeCYTE Breast Health Test, the flagship product of Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, was featured in a video...

SEATTLE, WA--(Marketwired - Aug 21, 2013) - Atossa Genetics Inc. (NASDAQ: ATOS) and its subsidiary The National Reference Laboratory for Breast Health (NRLBH), will display their products and...